Here, we identified that APL cells with defective PPARγ function is likely the essential factor triggering the dyslipidemia of APL patients by secreting resistin and subsequently disrupting the lipid metabolism of hepatocytes. The gene discussed is PPARG; the disease is metabolic syndrome.